Newron Pharmaceuticals – EKF interview

Newron Pharmaceuticals – EKF interview

Newron Pharmaceuticals — 1 video in collection

More on this equity

Newron Pharmaceuticals is focused on the development of its novel schizophrenia drug with two pivotal Phase III trials due to start in Q221. The company already has a marketed product for Parkinson’s disease, Xadago, sold in Europe and the US. A further Xadago trial for the treatment of Parkinson’s dyskinesia could add to US sales and may start in 2021.


You may also be interested in these:

Healthcare

Oryzon Genomics – executive interview

Healthcare

Basilea Pharmaceutica – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free